ライフサイエンスコーパス: human serum albumin

1 ter inhibition with a CCD inhibitor (MUXF(3)-human serum albumin).

2 whole blood was removed and replaced with 5% human serum albumin.

3 no binding between the peptide oligomers and human serum albumin.

4 ligands and transcription factors (TFs) and human serum albumin.

5 for 4 weeks with benzylpenicillin coupled to human serum albumin.

6 ed from purified bromelain glycopeptides and human serum albumin.

7 lasma and cerebrospinal fluid protein, i.e., human serum albumin.

8 ells loaded with benzylpenicillin coupled to human serum albumin.

9 titration calorimetry that JMS-053 binds to human serum albumin.

10 omplex two-site interaction of warfarin with human serum albumin.

11 ligand to boronic acids, such as lactate and human serum albumin.

12 of fluorescein isothiocyanate (FITC)-tagged human serum albumin.

13 idoglycan-polysaccharide (PG-APS) or control human serum albumin.

14 in were accomplished using infusions of 25% human serum albumin.

15 em containing a di-lysine motif derived from human serum albumin.

16 eters reckoned from the crystal structure of human serum albumin.

17 bound to lysines 195 and 475 of CLV-treated human serum albumin.

18 ultrafast hydration dynamics of the protein human serum albumin.

19 ne fusion of a single-chain human insulin to human serum albumin.

20 we determined that ATRAM binds reversibly to human serum albumin.

21 ublished X-ray crystallographic structure of human serum albumin.

22 not significantly reduced in the presence of human serum albumin.

23 reaction of a pendant maleimide ligand with human serum albumin.

24 specific binding of bovine serum albumin and human serum albumin.

25 xchange chromatography based purification of human serum albumin.

26 ain antibody fragment specific for mouse and human serum albumin.

27 teinylglycine, and beta-mercaptoethanol) and human serum albumin.

28 albumin, beta-lactoglobulin, soy protein and human serum albumin.

29 patient-years for the Eprex formulation with human serum albumin, 1 case per 100,000 patient-years fo

30 ient-years for the Eprex formulation without human serum albumin, 6 per 100,000 patient-years for the

31 onoclonal antibody, IgG2, and the effects of human serum albumin, a major blood protein, on this phas

32 ost completely removes p-cresyl sulfate from human serum albumin, a protein that these uremic toxins

33 ture for the clinical safety and efficacy of human serum albumin administration to critically ill pat

34 r of skin mast cells, and challenge with DNP-human serum albumin after passive sensitization induced

35 toxicants and toxic electrophiles react with human serum albumin (albumin); however, the chemistry of

36 1), 0.49 T, 37 degrees C) in the presence of human serum albumin, allowing a significant MRI signal i

37 their monomeric form, can seize copper from human serum albumin, an abundant copper-containing prote

38 The contents of two amide-AGEs in human serum albumin and apolipoprotein A-II were signifi

39 The ability to detect miRNA-21 in human serum albumin and bovine serum albumin was almost

40 the quantitative and qualitative analysis of human serum albumin and carbonic anhydrase in binary mix

41 n mice passively sensitized to dinitrophenol-human serum albumin and challenged intradermally.

42 mice passively sensitized with dinitrophenol-human serum albumin and challenged intradermally.

43 ime oxidized phospholipid adducts to LDL and human serum albumin and for the detection of glycosylati

44 the compounds displayed extensive binding to human serum albumin and had limited activity in cellular

45 Tryptic digests of human serum albumin and human lung epithelial cell lysat

46 robe is capable of detecting proteins, i.e., human serum albumin and lysozyme, with high specificity

47 tivity toward potential interferents such as human serum albumin and ovalbumin.

48 Human serum albumin and plasma components decreased DNA

49 rmation of radical-derived DMPO spin-trapped human serum albumin and, to a lesser extent, of DMPO-EPO

50 assessed with technetium Tc 99m radiolabeled human serum albumin, and a pharmacokinetic study was per

51 electrically charged macromolecules, such as human serum albumin, and larger neutral macromolecules s

52 process in samples of bovine serum albumin, human serum albumin, and lysozyme.

53 particles) with proteins (human transferrin, human serum albumin, and ovalbumin).

54 for caffeine and L-tryptophan, which bind to human serum albumin, and the antimalarial agent trimetho

55 tol, N-acetylcysteine, captopril, bovine and human serum albumins, and hydrogen sulfide, are reported

56 Using human serum albumin as a model, its sequence was exploit

57 Using nitrated human serum albumin as a model, we reduced the disulfide

58 Since the introduction of human serum albumin as a plasma expander in the 1940s, c

59 e was identified by X-ray crystallography in human serum albumin at drug site 3, which is also known

60 fect outcomes, administration of ultra-clean human serum albumin at protein concentrations equivalent

61 omers, 2,4- and 2,6-toluene diisocyanate, on human serum albumin at varying diisocyanate/protein rati

62 ther non-heme-containing proteins, including human serum albumin, beta-casein, and carbonic anhydrase

63 Human serum albumin binding assays indicated that the re

64 ivities with lipophilicity and the extent of human serum albumin binding is observed within this seri

65 Human serum albumin binding was measured by affinity hig

66 icals, medium-to-low lipophilicity, and high human serum albumin binding.

67 mer peptide, which lies in Subdomain IIIA of human serum albumin, blocks binding of all three antibod

68 Bovine and human serum albumin (BSA and HSA) are globular proteins

69 ravenous anesthetic (propofol) to bovine and human serum albumin (BSA and HSA) using isothermal titra

70 binding affinity between drug molecules and human serum albumin by combining nanoporous anodic alumi

71 ue to the heterogeneous nature of commercial human serum albumin (cHSA), other components, such as th

72 y-D-lysine-Le(b) hexasaccharide and an Le(b) human serum albumin conjugate not only inhibited adheren

73 R2 region of gp41, was engineered into a 1:1 human serum albumin conjugate through stable covalent at

74 the tryptic digests of three model proteins (Human Serum Albumin, creatine kinase, and myoglobin).

75 ella dysenteriae type 1 covalently linked to human serum albumin elicited O-SP-specific IgG in mice.

76 ocomposites of rare-earth nanomaterials with human serum albumin facilitated systemic biodistribution

77 ethylenetriamine pentaacetic acid-galactosyl-human serum albumin for evaluation of functional liver v

78 ides because of the high binding affinity of human serum albumin for fatty acids.

79 Median human serum albumin for OriCols was 14.9 mug/ml, whereas

80 We have also purified nitrated human serum albumin from an enriched sample of SJL mouse

81 lbumin molecule) in comparison to the plasma human serum albumin from healthy volunteers (22.9 +/- 4.

82 merit are presented for carbonic anhydrase, human serum albumin, gamma-globulins, and thermolysin.

83 ied DNA aptamers specifically bound glycated human serum albumin (GHSA), which is an intermediate mar

84 A new electrochemical biosensor based on the human serum albumin/graphene oxide/3-aminopropyl-trietho

85 y depleting highly abundant proteins such as human serum albumin (>10(10) more abundant than cTnI).

86 decreased binding to hemin, hemoglobin, and human serum albumin-hemin complex.

87 rious proteins such as beta-lactoglobulin A, human serum albumin, hemoglobin, and human carbonic anhy

88 The binding of JMS-053 to human serum albumin, however, did not markedly alter the

89 ats injected with PG-PS and 13 injected with human serum albumin (HSA) (control animals).

90 carbons has often been quantified via DNA or human serum albumin (HSA) adducts of the carcinogenic me

91 per, we describe a new modality of measuring human serum albumin (HSA) adsorption continuously on CH3

92 Kd) of individual PFOS and PFOA isomers with human serum albumin (HSA) and (ii) relative binding affi

93 nted with 10% dimethyl sulfoxide (DMSO), 15% human serum albumin (HSA) and 0.1% hyaluronans.

94 ml PSA as high as 7-fold increase versus the human serum albumin (HSA) and 8-fold increase versus the

95 ntify pH-dependent conformational changes in human serum albumin (HSA) and cytochrome C by monitoring

96 In the current study, MDI was reacted with human serum albumin (HSA) and hemoglobin (Hb) at molar r

97 ities towards the target biomarker proteins (human serum albumin (HSA) and human immunoglobulin G (HI

98 analysis by highly abundant proteins such as human serum albumin (HSA) and immunoglobulins (IgGs) whi

99 As model therapeutic proteins, we studied human serum albumin (HSA) and intravenous immunoglobulin

100 C. diphtheriae was also able to use human serum albumin (HSA) and myoglobin (Mb) but not hem

101 hanges of chloride binding to alpha-amylase, human serum albumin (HSA) and Omp32 with pH, and of alph

102 umina rugate filters (NAA-RFs) modified with human serum albumin (HSA) and reflectometric interferenc

103 ermodynamics and kinetics of binding between human serum albumin (HSA) and resveratrol (RES) or its a

104 sing testosterone and its transport proteins human serum albumin (HSA) and sex hormone binding globul

105 compounds from an NCI compounds library and human serum albumin (HSA) and three known ligands (ibupr

106 hierarchical structure for determination of human serum albumin (HSA) are designed and fabricated.

107 This approach is demonstrated using human serum albumin (HSA) as a model binding agent.

108 ormance affinity chromatography by employing human serum albumin (HSA) as a model protein.

109 is study was to investigate the potential of human serum albumin (HSA) as a solubilising agent/drug d

110 re synthesized using the circulatory protein human serum albumin (HSA) as a template, whose synthetic

111 resence of a high concentration (500 muM) of human serum albumin (HSA) as an interfering protein in t

112 The knowledge on human serum albumin (HSA) binding is of utmost importanc

113 Human serum albumin (HSA) binds 95% of Abeta in blood pl

114 onal isomers are transported to the liver by human serum albumin (HSA) but their precise binding loca

115 ermining binding sites of small molecules on human serum albumin (HSA) by competitive displacement of

116 and highly disulfide-bonded proteins such as human serum albumin (HSA) by online EC reduction of nonr

117 gth of perfluoroalkyl acid (PFAA) binding to human serum albumin (HSA) by use of the protein's native

118 Glycation of human serum albumin (HSA) can also be measured using thi

119 These additives interaction with human serum albumin (HSA) can exert considerable effect

120 Previously, we showed that human serum albumin (HSA) can increase foreign DNA acqui

121 Beside the regulation of fluid distribution, human serum albumin (HSA) carries other activities, such

122 d molecular length among sources and lots of human serum albumin (HSA) commercial preparations intend

123 cused on bovine serum albumin (BSA), leaving human serum albumin (HSA) comparatively understudied.

124 although the C-terminal domain III (DIII) of human serum albumin (HSA) contains the principal binding

125 munosensor using a simple optical system for human serum albumin (HSA) detection is developed.

126 ting molecularly imprinted polymer (MIP) for human serum albumin (HSA) determination using semi-coval

127 Despite knowing about the location of human serum albumin (HSA) drug binding sites and the res

128 ein nanoparticle (SPNP) based on polymerized human serum albumin (HSA) equipped with the cell-penetra

129 ned specifically to enhance interaction with human serum albumin (HSA) for drug delivery.

130 he kinetics and affinities of fibrinogen and human serum albumin (HSA) for TiO2, CeO2, Al2O3 and ZnO

131 to human A2, C1, and C2 domains presented as human serum albumin (HSA) fusion proteins.

132 Conjugation to human serum albumin (HSA) has emerged as a powerful appr

133 umins such as bovine serum albumin (BSA) and human serum albumin (HSA) have found a wide range of bio

134 The model for this work was human serum albumin (HSA) immobilized onto silica by the

135 s, we profiled adducts at the Cys34 locus of human serum albumin (HSA) in 29 nonsmoking Xuanwei and F

136 The label-free detection of human serum albumin (HSA) in aqueous buffer is demonstra

137 rize chemically induced protein unfolding of human serum albumin (HSA) in great detail.

138 s (Dh = 200 nm) which selectively respond to human serum albumin (HSA) in the presence of other thiol

139 jectives of this study were (i) to galactate human serum albumin (HSA) in vitro; (ii) to determine, b

140 we report that binding of retinoate (RA) to human serum albumin (HSA) increases the solid-state elec

141 The concentration of human serum albumin (HSA) indicates the health state of

142 e-chain variable fragment (scFv) fragment to human serum albumin (HSA) influences pH-dependent bindin

143 Human serum albumin (HSA) interacts with this family of

144 Human serum albumin (HSA) is a natural carrier protein p

145 Human serum albumin (HSA) is a potent inhibitor of Abeta

146 Human serum albumin (HSA) is a versatile transport prote

147 Human serum albumin (HSA) is an abundant plasma protein

148 Human serum albumin (HSA) is an abundant plasma protein

149 Quantitative and selective detection of human serum albumin (HSA) is demonstrated with a limit o

150 Enhanced nonenzymatic glycosylation (NEG) of human serum albumin (HSA) is observed in diabetic patien

151 pten was detected on four lysine residues of human serum albumin (HSA) isolated from tolerant patient

152 finity for PSMA and appropriate affinity for human serum albumin (HSA) may demonstrate a higher thera

153 The observed binding with human serum albumin (HSA) of the compounds having C-3 th

154 The effect of human serum albumin (HSA) on an immunokinetic assay for

155 Human serum albumin (HSA) or acetyl-Gly-Lys-O-methyl est

156 rats, rats receiving intravitreally injected human serum albumin (HSA) or vascular endothelial growth

157 ions, we loaded ATO onto folate (FA)-labeled human serum albumin (HSA) pretreated with glutathione (G

158 e of solution chemistry on the adsorption of human serum albumin (HSA) proteins on graphene oxide (GO

159 mustard (SM) produces a covalent adduct with human serum albumin (HSA) representing an established pl

160 Trypsin-digested, SDA-cross-linked human serum albumin (HSA) served as a test sample, yield

161 Human serum albumin (HSA) serves as a convenient and eas

162 Human serum albumin (HSA) serves not only as a physiolog

163 free bilirubin in blood serum samples using human serum albumin (HSA) stabilized gold nanoclusters (

164 In this work, human serum albumin (HSA) stabilized gold nanoclusters (

165 ic linkage of dibenzocyclooctyne-derivatized human serum albumin (HSA) through strain-promoted azide-

166 The ability of human serum albumin (HSA) to bind fatty acids (FA) in mu

167 tPA was camouflaged with human serum albumin (HSA) via a thrombin-cleavable pepti

168 he serum proteins apotransferrin (apoTf) and human serum albumin (HSA) was addressed as well.

169 A competitive immunoassay for detecting human serum albumin (HSA) was also demonstrated by dosin

170 ally determined binding affinity of DOX with human serum albumin (HSA) was considered to simplify the

171 The affinity of anthocyanins for human serum albumin (HSA) was determined by a fluorescen

172 boxylate (AC) in the chiral binding sites of human serum albumin (HSA) was studied using fluorescence

173 manized variant (huE06 v1.1) in complex with human serum albumin (HSA) were determined at 3- and 2.3-

174 cyanate (FITC) after fluorescent labeling of human serum albumin (HSA) with electromembrane extractio

175 -density-lipoprotein (VLDL) yields 1-3%, and human serum albumin (HSA) yields 0-2%.

176 on of complexes with albumin (in particular, human serum albumin (HSA)) are fundamental for the chara

177 Human serum albumin (HSA), an abundant component of huma

178 Human serum albumin (HSA), an important binding agent fo

179 Human serum albumin (HSA), an important serum competitor

180 of the complex between human FcRn, wild-type human serum albumin (HSA), and a human Fc engineered for

181 human glutathione S-transferase pi (hGSTP), human serum albumin (HSA), and bovine serum albumin (BSA

182 f diethylenetriaminepentaacetic acid (DTPA), human serum albumin (HSA), and cysteine.

183 ated for the analysis of carbonic anhydrase, human serum albumin (HSA), and gamma-globulin.

184 article starts with a brief introduction of human serum albumin (HSA), and then summarizes the mains

185 by additives, such as Triton X-100 (TX) and human serum albumin (HSA), are not fully understood.

186 In this work, human serum albumin (HSA), beta-casein, and recombinant

187 Three albumins have been considered, namely human serum albumin (HSA), fatty acid free HSA (ffHSA) a

188 abundantly expressed extracellular protein, human serum albumin (HSA), inhibits alphaS oligomer (alp

189 wing incubation of aliquots of the sera with human serum albumin (HSA), lipoylated HSA (HSA-LA), PDC-

190 port a method to enrich cysteinyl adducts of human serum albumin (HSA), representing biomarkers of ex

191 ein (human Kallikrein 2) and low response to human serum albumin (HSA), suggesting possible resilienc

192 , in the presence of physiological levels of human serum albumin (HSA), the r(1) relaxivity is amplif

193 P) of glucosamine (GlcN) with fibrinogen and human serum albumin (HSA), under simulated physiological

194 time exponential release of a model protein, human serum albumin (HSA), was observed from two differe

195 tein digestion protocols, the model protein, human serum albumin (HSA), was subjected to enzymatic di

196 enous inhibitor of Abeta self-association is human serum albumin (HSA), which binds approximately 90%

197 In this study we examined human serum albumin (HSA), which contained one to nine c

198 Examination of peptides derived from human serum albumin (HSA), which is a protein known to b

199 warfarin during their binding to the protein human serum albumin (HSA), with beta-cyclodextrin being

200 HNE adduction of blood proteins, such as human serum albumin (HSA), yields adducts that may serve

201 eins purified from human lung tissue [with a human serum albumin (HSA)-affinity column] identified th

202 llenges, we rationally developed a drug-free human serum albumin (HSA)-based therapeutic (KH-1) that

203 -oxide) prevented such processes by trapping human serum albumin (HSA)-centered radicals, in situ and

204 es CTX, bovine thyroglobulin (Bos d TG), and human serum albumin (HSA)-conjugated alpha-Gal.

205 t 50 mM(-1) s(-1) upon binding to Zn(II) and human serum albumin (HSA).

206 l library of putative MRI probes targeted to human serum albumin (HSA).

207 tose and l-ascorbic acid were incubated with human serum albumin (HSA).

208 was demonstrated by quantitatively detecting human serum albumin (HSA).

209 ng, the alpha(1)-acid-glycoprotein (AGP) and human serum albumin (HSA).

210 covalently bound to apomyoglobin (ApoMg) and human serum albumin (HSA).

211 tational docking with a crystal structure of human serum albumin (HSA).

212 lysis of BPDE adducts from lymphocyte DNA or human serum albumin (HSA).

213 reversibly to cysteine (Cys, position 34) in human serum albumin (HSA).

214 an method was used to study the glycation in human serum albumin (HSA).

215 e molecular details for the interaction with human serum albumin (HSA).

216 um or samples containing the binding protein human serum albumin (HSA).

217 n small, focused medicinal libraries against human serum albumin (HSA).

218 e binding of drugs to blood proteins such as human serum albumin (HSA).

219 mance affinity monolithic columns containing human serum albumin (HSA).

220 pounds were also found to bind to site II of human serum albumin (HSA).

221 rug readily forms a noncovalent complex with human serum albumin (HSA).

222 s onto proteins to increase their binding to human serum albumin (HSA).

223 detecting catechol estrogens (CEs)-adducted human serum albumin (HSA).

224 antages of unusually long serum half-life of human serum albumin (HSA).

225 A structures with strong binding affinity to human serum albumin (HSA).

226 to describe the interaction between 2PHE and human serum albumin (HSA).

227 deactivation was identified as domain III of human serum albumin (HSA); NMR solution structures of in

228 Human serum albumin (HSA, 66.5kDa) was used as a model p

229 longation was observed with carrier protein (human serum albumin [HSA] or dextran) alone.

230 egated serum albumin [MAA]) and (99m)Tc-HSA (human serum albumin [HSA]), was assessed.

231 -relevant delivery systems (liposomes and in human serum albumin [HSA]-fusion products) in combinatio

232 Human serum albumin, HSA, was immobilized onto the surfa

233 erns were obtained from five serum proteins (human serum albumin, immunoglobulin G, transferrin, fibr

234 modulation of aaRS levels to express mutant human serum albumin in excess of 150 mg/L in shake flask

235 ctApoSp) was reduced after immunization with human serum albumin in TLR4(-/-) mice.

236 predominant site of N-homocysteinylation in human serum albumin in vitro and in vivo.

237 ds in lysozyme and all 17 disulfide bonds in human serum albumin, including nested disulfide bonds an

238 50-fold, and physiological concentrations of human serum albumin increased k(2) 220-fold.

239 Human serum albumin is an endogenous ligand transport pr

240 Human serum albumin is indicated for the treatment of sh

241 Human serum albumin is modified by methylglyoxal in vivo

242 n (CPO) or diisopropylfluorophosphate (DFP): human serum albumin (K212, K414, K199, and K351), human

243 librium dissociation constant for Zn(2+) and human serum albumin (Kd = (5.62 +/- 0.93) x 10(-7) M) un

244 Conjugation of fatty acid, a natural human serum albumin ligand, to a therapeutic protein/pep

245 d selectivity against other proteins such as human serum albumin, lysozyme and insulin.

246 Addition of a human serum albumin molecule prolongs the half-life in a

247 (oxidation of cysteine in position 34 on the human serum albumin molecule) in comparison to the plasm

248 In one example, we show that a recombinant human serum albumin mutant containing a keto amino acid

249 t seen in rabbits injected with 125I-labeled human serum albumin (n=6).

250 more than 95% of model biochemical species (human serum albumin, neurotensin, creatinine, glycine, a

251 ate binding of cis-[Ru(phen)2(ImH)2](2+) and human serum albumin occurs via noncovalent interactions

252 easing amounts of antigen (2,4-dinitrophenyl-human serum albumin or ovalbumin) in the presence of ext

253 The six human serum albumin preparations analyzed contained a hi

254 Commercially available human serum albumin preparations and healthy volunteers.

255 for a large percentage of the composition of human serum albumin preparations used for the treatment

256 Six commercially available human serum albumin preparations were analyzed by high-p

257 erents investigated (NaHS, NH4OH, NaSCN, and human serum albumin) produced a signal that could be int

258 Noncovalent binding of biopharmaceuticals to human serum albumin protects against enzymatic degradati

259 esonators is demonstrated for the example of human serum albumin protein adsorption from aqueous buff

260 er, lapatinib release from a nanoshell-based human serum albumin protein host complex resulted in inc

261 for each of four proteins consisting of BSA, human serum albumin, rabbit IgG, and protein G were dyna

262 Lot-to-lot variability in native human serum albumin ranged between 4.8% and 11.2% in thr

263 of the emodin and aloe-emodin derivatives to human serum albumin ranged from -7.30 and -10.62 kcal/mo

264 strong and specific affinity of recombinant human serum albumin (rHSA) towards cholesteryl-modified

265 phytase activity in rice-derived recombinant human serum albumin (rHSA) using a sensitive, label-free

266 present in tobacco smoke, were reacted with human serum albumin (SA) and formed labile sulfenamide o

267 rawn and replaced with an equal volume of 5% human serum albumin-saline mixture) to reduce [Hb] (Low

268 the extracellular domain of EphB4 fused with human serum albumin (sEphB4-HSA).

269 Human serum albumin species with a bound Cys34 account f

270 process and present human serum albumin to a human serum albumin-specific and DR4 allele-restricted T

271 ps (glutamate in antibody 34E4 and lysine in human serum albumin) surrounded by relatively nonpolar g

272 wed higher solubilities and lower binding to human serum albumin than that of Mocetinostat.

273 specific DR4 allele, can process and present human serum albumin to a human serum albumin-specific an

274 he administration of these oxidized forms of human serum albumin to critically ill patients warrants

275 whole blood was removed and replaced with 5% human serum albumin to reduce haemoglobin concentration

276 The addition of human serum albumin to the tri-specific inhibitor could

277 xploit the intrinsic transport properties of human serum albumin to tune the blood circulatory half-l

278 Methylglyoxal reacted with human serum albumin under physiological conditions to fo

279 Here, we examine the binding of an ABD to human serum albumin using isothermal titration calorimet

280 l of antibody 34E4 and an X-ray structure of human serum albumin was accomplished.

281 Human serum albumin was added at a final concentration o

282 Also, for the purpose of comparison, human serum albumin was analyzed in the plasma of health

283 Recombinant human serum albumin was even more striking with lifetime

284 Finally, human serum albumin was found to bind NO2-CLA both non-c

285 herefore, the interaction between KP1019 and human serum albumin was investigated by means of X-ray c

286 In these experiments, human serum albumin was modified in a myeloperoxidase-me

287 When human serum albumin was modified minimally with methylgl

288 Human serum albumin was used as a model protein to detec

289 The interaction of L-tryptophan with human serum albumin was used as a model system to test t

290 human IgE even when human IgG, thrombin, and human serum albumin were present at 100-fold concentrati

291 ng OCT interference from a standard protein, human serum albumin, where all of the unique peaks contr

292 Human serum albumin, which contains a single tryptophan,

293 hosphatase 4A3 binds to at least one site on human serum albumin, which is likely to extend the compo

294 We focused on modifications to Cys34 in human serum albumin, which is responsible for scavenging

295 oci of blood proteins, particularly Cys34 of human serum albumin, which is the dominant scavenger of

296 aRIIIA-specific antibody linked in tandem to human serum albumin, which retained FcgammaR-binding act

297 ly redock perfluorooctanesulfonate (PFOS) to human serum albumin with deviations smaller than 2 A.

298 y occurs as a consequence of the reaction of human serum albumin with homocysteine thiolactone.

299 an antibody binding site, HSA Peptide 40, on human serum albumin with nanomolar affinity for all thre

300 I) binds to the multimetal binding site A on human serum albumin with two inner-sphere water ligands